Literature DB >> 20233273

Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype.

Jorge Massare1, Jeff M Berry, Xiang Luo, Farhana Rob, Janet L Johnstone, John M Shelton, Rhonda Bassel-Duby, Joseph A Hill, R Haris Naseem.   

Abstract

OBJECTIVES: We sought to define the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium.
BACKGROUND: Multiple cellular events that occur during pathological remodeling of the failing ventricle are implicated in the genesis of ventricular tachycardia (VT), including interstitial fibrosis. Recent studies suggest that ventricular fibrosis is reversible, and current anti-remodeling therapies attenuate ventricular fibrosis. However, the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium is currently not well defined.
METHODS: Class II histone deacetylases (HDACs) have been implicated in promoting collagen biosynthesis. As these enzymes are inhibited by protein kinase D1 (PKD1), we studied mice with cardiomyocyte-specific transgenic over-expression of a constitutively active mutant of PKD1 (caPKD). caPKD mice were compared with animals in which cardiomyopathy was induced by severe thoracic aortic banding (sTAB). Hearts were analyzed by echocardiographic and electrocardiographic means. Interstitial fibrosis was assessed by histology and quantified biochemically. Ventricular arrhythmias were induced by closed-chest, intracardiac pacing.
RESULTS: Similar degrees of hypertrophic growth, systolic dysfunction and mortality were observed in the two models. In sTAB mice, robust ventricular fibrosis was readily detected, but myocardial collagen content was significantly reduced in caPKD mice. As expected, VT was readily inducible by programmed stimulation in sTAB mice and VT was less inducible in caPKD mice. Surprisingly, episodes of VT manifested longer cycle lengths and longer duration in caPKD mice.
CONCLUSION: Attenuated ventricular fibrosis is associated with reduced VT inducibility, increased VT duration, and significantly longer arrhythmia cycle length.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233273      PMCID: PMC3703442          DOI: 10.1111/j.1540-8167.2010.01736.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  38 in total

Review 1.  Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy.

Authors:  Ichiro Manabe; Takayuki Shindo; Ryozo Nagai
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

2.  Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts.

Authors:  Karl T Weber
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

3.  Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts.

Authors:  Victor V Petrov; Robert H Fagard; Paul J Lijnen
Journal:  Hypertension       Date:  2002-02       Impact factor: 10.190

4.  Cardiac hypertrophy is not a required compensatory response to short-term pressure overload.

Authors:  J A Hill; M Karimi; W Kutschke; R L Davisson; K Zimmerman; Z Wang; R E Kerber; R M Weiss
Journal:  Circulation       Date:  2000-06-20       Impact factor: 29.690

5.  Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function.

Authors:  Joseph A Hill; Beverly Rothermel; Ki-Dong Yoo; Barry Cabuay; Elaine Demetroulis; Robert M Weiss; William Kutschke; Rhonda Bassel-Duby; R Sanders Williams
Journal:  J Biol Chem       Date:  2002-01-10       Impact factor: 5.157

Review 6.  What causes sudden death in heart failure?

Authors:  Gordon F Tomaselli; Douglas P Zipes
Journal:  Circ Res       Date:  2004-10-15       Impact factor: 17.367

7.  Implications of ventricular arrhythmia vulnerability during murine electrophysiology studies.

Authors:  Colin T Maguire; Hiroko Wakimoto; Vickas V Patel; Peter E Hammer; Kimberlee Gauvreau; Charles I Berul
Journal:  Physiol Genomics       Date:  2003-09-29       Impact factor: 3.107

8.  Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.

Authors:  William B Lea; Eun Soo Kwak; James M Luther; Susan M Fowler; Zuofei Wang; Ji Ma; Agnes B Fogo; Nancy J Brown
Journal:  Kidney Int       Date:  2009-02-18       Impact factor: 10.612

9.  Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5.

Authors:  Rick B Vega; Brooke C Harrison; Eric Meadows; Charles R Roberts; Philip J Papst; Eric N Olson; Timothy A McKinsey
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

Review 10.  Cardiac hypertrophy: the good, the bad, and the ugly.

Authors:  N Frey; E N Olson
Journal:  Annu Rev Physiol       Date:  2003-01-09       Impact factor: 19.318

View more
  16 in total

1.  Increased myocardial native T1 relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrhythmia.

Authors:  Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat
Journal:  J Magn Reson Imaging       Date:  2017-07-24       Impact factor: 4.813

2.  Effect of spironolactone on patients with atrial fibrillation and structural heart disease.

Authors:  Ryan S Williams; James A deLemos; Vassilis Dimas; Joan Reisch; Joseph A Hill; R Haris Naseem
Journal:  Clin Cardiol       Date:  2011-06-14       Impact factor: 2.882

3.  Effect of angiotensin-converting enzyme inhibitors and receptor blockers on appropriate implantable cardiac defibrillator shock in patients with severe systolic heart failure (from the GRADE Multicenter Study).

Authors:  Wael A AlJaroudi; Marwan M Refaat; Robert H Habib; Laila Al-Shaar; Madhurmeet Singh; Rebecca Gutmann; Heather L Bloom; Samuel C Dudley; Patrick T Ellinor; Samir F Saba; Alaa A Shalaby; Raul Weiss; Dennis M McNamara; Indrani Halder; Barry London
Journal:  Am J Cardiol       Date:  2015-01-15       Impact factor: 2.778

4.  Reversibility of adverse, calcineurin-dependent cardiac remodeling.

Authors:  Jeff M Berry; Vien Le; David Rotter; Pavan K Battiprolu; Bennett Grinsfelder; Paul Tannous; Jana S Burchfield; Michael Czubryt; Johannes Backs; Eric N Olson; Beverly A Rothermel; Joseph A Hill
Journal:  Circ Res       Date:  2011-06-23       Impact factor: 17.367

5.  Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy.

Authors:  Vassilis Dimas; Colby Ayers; James Daniels; Jose A Joglar; Joseph A Hill; R Haris Naseem
Journal:  Pacing Clin Electrophysiol       Date:  2010-10-14       Impact factor: 1.976

6.  Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy?

Authors:  Hrayr S Karagueuzian
Journal:  Am J Cardiovasc Dis       Date:  2011-06-12

Review 7.  Pathological ventricular remodeling: mechanisms: part 1 of 2.

Authors:  Jana S Burchfield; Min Xie; Joseph A Hill
Journal:  Circulation       Date:  2013-07-23       Impact factor: 29.690

8.  Differential Regulatory Role of Soluble Klothos on Cardiac Fibrogenesis in Hypertension.

Authors:  Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun
Journal:  Am J Hypertens       Date:  2016-08-19       Impact factor: 2.689

9.  The Prognostic Role of Tissue Characterisation using Cardiovascular Magnetic Resonance in Heart Failure.

Authors:  Robert D Adam; James Shambrook; Andrew S Flett
Journal:  Card Fail Rev       Date:  2017-11

10.  The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy.

Authors:  Domenico M Taglieri; Keven R Johnson; Brian T Burmeister; Michelle M Monasky; Matthew J Spindler; Jaime DeSantiago; Kathrin Banach; Bruce R Conklin; Graeme K Carnegie
Journal:  J Mol Cell Cardiol       Date:  2013-10-23       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.